Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Issue 2 (17th September 2013)

• Record Type: Journal Article
• Authors: Millot, Frédéric; Claviez, Alexander; Leverger, Guy; Corbaciglu, Selim; Groll, Andreas H.; Suttorp, Meinolf
• Is Part Of: Pediatric blood & cancer. Volume 61:Issue 2(2014:Feb.)
• Page Start: 355
• Page End: 357
• Publication Date: 2013-09-17
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24521
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24521-sec-0001" sec-type="section"> <p>Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for &lt;2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR. Pediatr Blood Cancer 2014;61:355–357. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>